Sign up for the Abwiz Bio Newsletter to get actionable advice and exclusive deals direct to your inbox.
Cannabinoid receptor type 2 (CB2) (R4F4) rabbit mAb
20 μL is enough antibody for at least 20 Western blots.
Cannabinoid receptors (CB) are members of the class A G protein-coupled receptor (GPCR) family. CB1 and CB2 display about 44% amino acid sequence homology (1,2). There are more than 100 different plant-based cannabinoids with different affinities to cannabinoid receptors. The psychoactive drug 9-tetrahydrocannabinol (THC) is the most prominent one. CB1 receptors are mainly expressed in the brain (cerebral cortex, hippocampus, basal ganglia, and cerebellum) as well as peripheral tissues including leukocytes, spleen, tonsils, thymus, heart, and vasculature (3,4). They promote psychotropic and behavioral effects of cannabinoids. Whereas CB2 receptors are expressed in variety of systems including central nervous system (CNSs), cardiovascular system, respiratory system, bone, gastrointestinal system, liver and the reproductive system (5-7). CB2 receptors are attractive target for development for immune-modulating agents, pain management, osteoporosis, and the treatment of liver diseases (8-10).
|Cross Reactivity||Predicted to work with mouse, rat and other homologues.|
|Formulation||1X PBS, 0.09% NaN3, 0.2% BSA|
|Recommended Usage||For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells or 5 µL per 100 µL of staining volume. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.|
|Pseudonyms||Cannabinoid receptor 2, CB-2, CB2, hCB2, CX5, CNR2|
|References||1. Matsuda LA, et al., (1990) Nature, 346:561-564.
2. Moro O, et al., (1993) J Biol Chem, 268:22273-22276.
3. Howlett AC, et al., (2002) Pharmacol Rev, 54:161-202.
4. Bonz A, et al., (2003) J Cardiovasc Pharmacol, 41:657-664.
5. Onaivi ES, et al., (2006) Ann NY Acad Sci, 1074:514-536.
6. Bab I, and Zimmer A, (2008) Br J Pharmacol, 153:182-188.
7. Maccarrone M, (2008) Br J Pharmacol, 153:189-198.
8. Mbvundula EC, et al., (2004) Inflammopharmacology, 12:99-114.
9. Guindon J, and Hohmann AG, (2008) Br J Pharmacol, 153:319-334.
10. Feng R, et al., (2014) BMC Pharmacol Toxicol, 15:30.